1-8 of 8
Yong Du
Close
Sort by
Journal Articles

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Vasiliki Michalarea, MD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Siraj Yusuf, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma Attygalle, Simon O'Connor, Bhupinder Sharma, Yong Du, Imene Zerizer, Alan Horwich, Gillian Ross, Andrea Kuhnl, Sunil Iyengar, Ian Chau, MD, David Cunningham
Journal: Blood
Blood (2018) 132 (Supplement 1): 4240.
https://doi.org/10.1182/blood-2018-99-119560
Published: 2018
Journal Articles

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Andrea Kuhnl, MD, Clare Peckitt, Bijal Patel, Kirit M Ardeshna, MD, Marian P Macheta, John Radford, MD, Rod Johnson, Shankaranarayana Paneesha, Sarah Barton, Ian Chau, MD, Martin F Kaiser, MD, Ruwaida Begum, Nicola Valeri, Andrew Wotherspoon, Yong Du, Imene Zerizer, David Cunningham, MD FRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 2829.
https://doi.org/10.1182/blood.V130.Suppl_1.2829.2829
Published: 2017
Journal Articles

Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Mary Gleeson, FRCPath, Eliza A Hawkes, MD, Clare Peckitt, MSc, Andrew Wotherspoon, FRCPath, Ayoma Attygalle, PhD, Bhupinder Sharma, MD, Yong Du, MD, Mark Ethell, MD, Michael Potter, PhD, Claire Dearden, MD, Alan Horwich, MD, Ian Chau, MD, David Cunningham, FMedSci
Journal: Blood
Blood (2014) 124 (21): 1719.
https://doi.org/10.1182/blood.V124.21.1719.1719
Published: 2014
Journal Articles

When is a predose a dose too much?

Tim Illidge, Yong Du
Journal: Blood
Blood (2009) 113 (23): 6034–6035.
https://doi.org/10.1182/blood-2009-03-208918
Published: 2009
Journal Articles

Phase 1/2 study of fractionated 131 I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Clinical Trials & Observations
Tim M. Illidge, Mike Bayne, Nicholas S. Brown, Samantha Chilton, Mark S. Cragg, Martin J. Glennie, Yong Du, Valerie Lewington, James Smart, James Thom, Maureen Zivanovic, Peter W. M. Johnson
Journal: Blood
Blood (2009) 113 (7): 1412–1421.
https://doi.org/10.1182/blood-2008-08-175653
Published: 2009
Journal Articles

A Nova EPO-Fusion Protein with Prolonged Half-Life in Circulation and Enhanced Activity In Vivo.

Haitao Wang, MD, Yong Du, Ph.D., Rui Zhang, Ph.D., Jin Xu, B.S., Longbin Liu, MD
Journal: Blood
Blood (2006) 108 (11): 1301.
https://doi.org/10.1182/blood.V108.11.1301.1301
Published: 2006
Journal Articles

Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin’s Lymphoma (NHL).

Tim M. Illidge, MD, PhD, Mike C. Bayne, MD, Maureen Zivanovic, Yong Du, MD, Valerie Lewington, MD, Johnson W. Peter, MD
Journal: Blood
Blood (2004) 104 (11): 131.
https://doi.org/10.1182/blood.V104.11.131.131
Published: 2004
Journal Articles

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

Yong Du, Jamie Honeychurch, Mark S. Cragg, Mike Bayne, Martin J. Glennie, Peter W. M. Johnson, Tim M. Illidge
Journal: Blood
Blood (2004) 103 (4): 1485–1494.
https://doi.org/10.1182/blood-2003-06-2037
Published: 2004